Haemonetics

Secular Trends Will Fuel Expansion In Blood Management Solutions

AnalystHighTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

29 Apr 25

Updated

15 Aug 25

AnalystHighTarget's Fair Value

US$107.86

49.7% undervalued

15 Aug

US$54.30

-26.7%

4.0%

Author's Valuation

US$107.9

49.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25
Fair value Decreased 0.13%

AnalystHighTarget Fair Value

US$107.9

49.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

3.34%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.56%

Calculation

US$293.93m

Earnings '28

19.71x

PE Ratio '28

US$5.79b

Market Cap '28

US$5.79b

Market Cap '28

42.52m

No. shares '28

US$136.26

Share Price '28

US$136.26 Share Price '28

Discounted to 2025 @ 8.55% p.a.

US$106.53

Fair Value '25

Secular Trends Will Fuel Expansion In Blood Management Solutions

Shared on07 May 25Fair value Decreased 0.13%

Shared on07 May 25
Fair value Decreased 0.13%